# A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

> **NCT07275814** · PHASE3 · RECRUITING · sponsor: **Shanghai Shengdi Pharmaceutical Co., Ltd** · enrollment: 250 (estimated)

## Conditions studied

- For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

## Interventions

- **DRUG:** HRS-9231 Injection
- **DRUG:** Gadobutrol Injection
- **DEVICE:** Magnetic Resonance Imaging (MRI)

## Key facts

- **NCT ID:** NCT07275814
- **Lead sponsor:** Shanghai Shengdi Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2026-04
- **Final completion:** 2026-05
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275814, "A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07275814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*